Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 10;13(9):639.
doi: 10.3390/toxins13090639.

Biomarkers of Uremic Cardiotoxicity

Bojan Stopic  1 , Sandra Dragicevic  2 , Branislava Medic-Brkic  3 , Aleksandra Nikolic  2 , Marko Stojanovic  3 , Sreten Budisavljevic  4 , Nada Dimkovic  1
Affiliations

Biomarkers of Uremic Cardiotoxicity

Bojan Stopic et al. Toxins (Basel). .

Abstract

Cardiovascular (CV) morbidity and mortality increase along with the progression of chronic kidney disease (CKD). The potential novel biomarkers of cardiotoxicity have been tested with the aim of the early detection of patients at high CV risk, and among them are markers of inflammation, oxidative stress, acute renal injury, and microRNAs. The study analyzed biomarkers in non-dialysis-dependent (NDD; stage 3a-4 CKD) and dialysis-dependent (DD) CKD patients. The prospective cohort study included 87 patients who were followed for 18 months, during which period newly occurred CV events were recorded. Cox regression analysis confirmed serum albumin, urea, interventricular septum thickness diameter (IVST), the use of calcium antagonist, and erythropoiesis-stimulating agent to be significant predictors of CV outcome. No significant difference was observed in biomarkers of inflammation, oxidative stress, acute kidney injury (IL-18, CRP, ferritin, IMA, SOD, NGAL, and KIM-1), and miR-133a, in regards to the presence/absence of CV event, CV death, and left ventricular hypertrophy. Serum albumin, urea, IVST, and the use of calcium antagonist and erythropoiesis-stimulating agents were confirmed to be factors associated with CV events in CKD patients. Apart from traditional risk factors, new research is needed to define novel and reliable biomarkers of cardiotoxicity in CKD patients.

Keywords: acute renal injury; biomarkers; cardiovascular event; inflammation; microRNAs; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. GBD Chronic Kidney Disease Collaboration Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–733. doi: 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed
    1. Vanholder R., Massy Z., Argiles A., Spasovski G., Verbeke F., Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 2005;20:1048–1056. doi: 10.1093/ndt/gfh813. - DOI - PubMed
    1. Subbiah A.K., Chhabra Y.K., Mahajan S. Cardiovascular disease in patients with chronic kidney disease: A neglected subgroup. Hear. Asia. 2016;8:56–61. doi: 10.1136/heartasia-2016-010809. - DOI - PMC - PubMed
    1. Foley R.N., Herzog C.A., Collins A.J. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney Int. 2002;62:1784–1790. doi: 10.1046/j.1523-1755.2002.00636.x. - DOI - PubMed
    1. McCullough P.A., Chan C.T., Weinhandl E.D., Burkart J.M., Bakris G.L. Intensive hemodialysis, left ventricular hypertrophy, and cardiovascular disease. Am. J. Kidney Dis. 2016;68:S5–S14. doi: 10.1053/j.ajkd.2016.05.025. - DOI - PubMed